translational-safety

Name: translational-safety
Availability: InStock
Author: Inflexa

Integrate CTCAE v5 grading, CYP metabolism, and FAERS signal detection for safety assessments.

29|3|Updated Jun 11, 2026

Search Tags:#safety #biomarkers #pharmacovigilance #toxicology #faers #ctcae

Ready to run

npx skills add https://github.com/inflexa-ai/inflexa --skill translational-safety

💬 Prompt for ChatGPT / Claude Chat▼

Please help me install this Agent Skill.
Skill: translational-safety
Source: https://github.com/inflexa-ai/inflexa/tree/main/skills/translational-safety
Command: npx skills add https://github.com/inflexa-ai/inflexa --skill translational-safety

SYSTEM DOCUMENTATION & REQUIREMENTS

💡 This Skill requires numpy, pandas, matplotlib, scipy, and includes references (resource) components.

What problem does it solve?

This skill addresses the complexity of translational safety assessments by providing a structured framework for evaluating drug toxicity, adverse event grading, and metabolic liabilities.

Core Features & Use Cases

Safety Assessment: Standardizes CTCAE v5 grading for clinical and laboratory safety data across organ systems including hepatic, renal, and cardiac.
Liability Screening: Facilitates rapid off-target safety panel lookups and CYP metabolism risk evaluation to identify potential drug-drug interactions.
Pharmacovigilance: Enables automated signal detection from FAERS data using established disproportionality measures like PRR, ROR, and IC.

Quick Start

Use the translational-safety skill to screen my candidate drug list against the safety panel and report any potential organ-specific toxicity signals.

Frequently Asked Questions about translational-safety

High-intent search queries and answers about installing and using this skill.

FAQPage Schema

How do I perform pharmacovigilance signal detection from FAERS data?▼

Pharmacovigilance signal detection from FAERS data uses disproportionality measures like PRR, ROR, and IC to identify potential safety signals. This process analyzes FAERS reporting metrics to systematically evaluate adverse event risks.

What is the best way to grade clinical adverse events using CTCAE v5 for organ-specific toxicity?▼

Grading clinical adverse events using CTCAE v5 standardizes safety assessments across hepatic, renal, and cardiac organ systems. This approach evaluates clinical and laboratory safety data to identify organ-specific toxicity risks.

Can I screen candidate drugs for CYP metabolism risk and drug-drug interactions?▼

You can screen candidate drugs for CYP metabolism risk and drug-drug interactions by evaluating metabolic liabilities. This screening identifies potential off-target safety panels and CYP enzyme profile risks.

Does this safety pharmacology workflow require structured clinical lab data and omics features?▼

This safety pharmacology workflow requires structured clinical lab data, omics features, and FAERS reporting metrics. Structured analysis of these inputs is necessary to identify potential safety signals and toxicity risks.

How do I identify organ-specific safety biomarkers in translational medicine workflows?▼

Identify organ-specific safety biomarkers in translational medicine workflows by integrating clinical adverse event grading with metabolic liability screening. This evaluates drug-drug interactions, CYP enzyme profiles, and toxicity risks.